We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pharma bosses faced a grilling from the US Senate’s Finance Committee over the high price of branded prescription drugs in the US compared with other developed countries.
Shire fought hard to stop it, but no dice: CSL has now launched its hereditary angioedema med Haegarda, and it’s done so with its eye on Shire’s market share.
The UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme (MSD) of operating an anti-competitive discount scheme for its medicine Remicade.